地中海饮食与低FODMAP饮食在非便秘性刺激性肠综合征患者中的有效性:试点随机对照试验
Prashant Singh1, Gregory Dean1, Sofia Iram1
1Divsion of Gastroenterology and Hepatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, USA.
Neurogastroenterology and motility
|April 24, 2025
概括
地中海饮食 (MD) 提供了刺激性肠综合征 (IBS) 患者的症状缓解,但低发酵性橄,二,单糖和多饮食 (LFD) 在这项试点研究中显示出更大的症状改善.
科学领域:
- 胃肠病学 胃肠病学
- 饮食科学 饮食科学
- 临床营养学 临床营养学
背景情况:
- 地中海饮食 (MD) 已被提出用于刺激性肠综合征 (IBS) 管理,但其比较有效性尚未得到充分证实.
- 低发酵性橄糖,二糖,单糖和多醇饮食 (LFD) 是IBS的常见饮食干预措施.
- 这项研究旨在在IBS患者中比较MD与LFD的疗效.
研究的目的:
- 为了比较地中海饮食 (MD) 与低发酵性橄糖,二糖,单糖和多醇饮食 (LFD) 的疗效,用于IBS-D或IBS-M患者的症状管理.
- 评估IBS患者在饮食干预后的症状缓解,包括腹痛和胀气.
主要方法:
- 一项试点可行性随机对照试验 (RCT),涉及被诊断患有腹主导性IBS (IBS-D) 或混合肠道模式IBS (IBS-M) 的成年患者.
- 参与者被随机分配到接受地中海饮食 (MD) 或低发酵性橄,二,单糖和多饮食 (LFD) 四周,并提供餐点.
- 主要终点:在4周中的2周内,患者的比例达到≥30%的腹痛强度下降. 二级终点包括IBS症状严重程度得分 (IBS-SSS) 和充分缓解 (IBS-AR).
主要成果:
- 在26名随机选择的患者中,有20人完成了研究 (每组10人).
- 在MD组中,73%的患者达到主终点,而LFD组的81.8% (p=1.0) 达到主终点.
- 与MD组相比,LFD组在4周的时间内显示出IBS-SSS的显着较大减少 (p=0.02),并且在数值上显示出更高的足够缓解率和IBS-SSS响应者状态.
结论:
- 地中海饮食 (MD) 为IBS-D和IBS-M患者提供症状缓解.
- 在这项试点研究中,低发酵性橄糖,二糖,单糖和多醇饮食 (LFD) 与MD相比,显示了更高的缓解症状.
- 更大的,现实世界的饮食比较研究是必要的,以建立在IBS管理中MD的常规建议.
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
236
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
236
Drugs for Treatment of Diarrhea-Predominant IBS
117
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
117
Drugs for Treatment of Constipation-Predominant IBS
109
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
109
Irritable Bowel Syndrome III: Medical and Nursing Management
117
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
117
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
96
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
96
What is Monogastric Digestion?
69.6K
The human body contains a monogastric digestive system. In a monogastric digestive system, the stomach only contains one chamber in which it digests food. Several other animal species also have monogastric digestive systems, including pigs, horses, dogs, and birds. This chapter, however, focuses on the human digestive system.
69.6K


